Galecto Biotech Books $89 Million in Series C Financing to Develop Fibrosis Candidate

Galecto Biotech Books $89 Million in Series C Financing to Develop Fibrosis Candidate

Source: 
CP Wire
snippet: 

Galecto Biotech AB, the leading developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, today announced the successful closing of a €79 million series C financing co-led by Ysios Capital and OrbiMed.